Becton Dickinson 관리

관리 기준 확인 3/4

Becton Dickinson CEO는 Tom Polen, Apr2017 에 임명되었습니다 의 임기는 7.58 년입니다. 총 연간 보상은 $ 17.31M, 7.6% 로 구성됩니다. 7.6% 급여 및 92.4% 보너스(회사 주식 및 옵션 포함). 는 € 12.50M 가치에 해당하는 회사 주식의 0.02% 직접 소유합니다. 12.50M. 경영진과 이사회의 평균 재임 기간은 각각 2.9 년과 7 년입니다.

주요 정보

Tom Polen

최고 경영자

US$17.3m

총 보상

CEO 급여 비율	7.6%
CEO 임기	7.6yrs
CEO 소유권	0.02%
경영진 평균 재임 기간	2.9yrs
이사회 평균 재임 기간	7yrs

최근 관리 업데이트

Recent updates

CEO 보상 분석

Tom Polen 의 보수는 Becton Dickinson 의 수익과 비교하여 어떻게 변경되었나요?
날짜	총 보상	급여	회사 수익
Jun 30 2024	n/a	n/a	US$1b
Mar 31 2024	n/a	n/a	US$1b
Dec 31 2023	n/a	n/a	US$1b
Sep 30 2023	US$17m	US$1m	US$1b
Jun 30 2023	n/a	n/a	US$2b
Mar 31 2023	n/a	n/a	US$2b
Dec 31 2022	n/a	n/a	US$1b
Sep 30 2022	US$17m	US$1m	US$2b
Jun 30 2022	n/a	n/a	US$1b
Mar 31 2022	n/a	n/a	US$1b
Dec 31 2021	n/a	n/a	US$1b
Sep 30 2021	US$14m	US$1m	US$2b
Jun 30 2021	n/a	n/a	US$1b
Mar 31 2021	n/a	n/a	US$1b
Dec 31 2020	n/a	n/a	US$2b
Sep 30 2020	US$12m	US$952k	US$245m
Jun 30 2020	n/a	n/a	US$786m
Mar 31 2020	n/a	n/a	US$923m
Dec 31 2019	n/a	n/a	US$760m
Sep 30 2019	US$6m	US$900k	US$1b
Jun 30 2019	n/a	n/a	US$784m
Mar 31 2019	n/a	n/a	US$926m
Dec 31 2018	n/a	n/a	US$894m
Sep 30 2018	US$6m	US$850k	US$159m

보상 대 시장: Tom 의 총 보상 ($USD 17.31M )은 Austrian 시장( $USD 4.40M ).

보상과 수익: Tom 의 보상은 지난 한 해 동안 회사 성과와 일치했습니다.

CEO

Tom Polen (51 yo)

7.6yrs

테뉴어

US$17,309,938

보상

Mr. Thomas E. Polen, Jr., also known as Tom, serves as Chief Executive Officer and Director at Becton, Dickinson and Company since January 28, 2020. Mr. Polen has been Director at Walgreens Boots Alliance,...

리더십 팀

이름	위치	테뉴어	보상	소유권
Thomas Polen	President	7.6yrs	US$17.31m	0.020% € 12.5m
Christopher DelOrefice	Executive VP & CFO	3.2yrs	US$5.21m	0.0044% € 2.7m
Shana Neal	Executive VP & Chief People Officer	2.6yrs	US$5.89m	0.0057% € 3.5m
Michael Garrison	Executive VP & President of Medical segment	2.2yrs	US$3.65m	0.0019% € 1.1m
Thomas Spoerel	Senior VP	5.1yrs	데이터 없음	0.00071% € 435.4k
Elizabeth McCombs	Executive VP & Chief Technology Officer	3.6yrs	데이터 없음	데이터 없음
Joseph Smith	Senior VP	3yrs	데이터 없음	데이터 없음
Denise Fleming	Executive VP of Technology & Global Services and Chief Information Officer	2.8yrs	데이터 없음	데이터 없음
Greg Rodetis	Head of Investor Relations	1.1yrs	데이터 없음	데이터 없음
Michelle Quinn	Executive VP & General Counsel	1.8yrs	데이터 없음	0.0017% € 1.0m
Claudia Curtis	Senior VP	no data	데이터 없음	데이터 없음
Carla Burigatto	Senior VP & Chief Communications Officer	no data	데이터 없음	데이터 없음

2.9yrs

평균 재임 기간

53.5yo

평균 연령

경험이 풍부한 관리: BDX 의 관리팀은 경험 ( 2.9 년 평균 재직 기간)으로 간주됩니다.

이사회 구성원

이름	위치	테뉴어	보상	소유권
Thomas Polen	President	4.8yrs	US$17.31m	0.020% € 12.5m
Joseph Smith	Senior VP	3yrs	데이터 없음	데이터 없음
John DeFord	Co-Chair of Scientific Advisory Board	3.5yrs	데이터 없음	데이터 없음
Robert Eckert	Independent Director	8.2yrs	US$362.77k	0.0028% € 1.7m
Timothy Ring	Independent Director	7.8yrs	US$332.78k	0.020% € 12.5m
Jeffrey Henderson	Independent Director	6.3yrs	US$357.78k	0.0019% € 1.2m
Christopher Ian Jones	Independent Director	14.3yrs	US$362.78k	0.0074% € 4.5m
Bertram Scott	Lead Independent Director	22.2yrs	US$372.78k	0.012% € 7.5m
Catherine Burzik	Independent Director	11.8yrs	US$357.78k	0.0046% € 2.8m
William Brown	Independent Director	2.8yrs	US$332.78k	0.00087% € 533.5k
Claire Fraser-Liggett	Member of Scientific Advisory Board & Independent Director	18yrs	US$340.15k	0.0078% € 4.8m
Carrie Byington	Independent Director	3.1yrs	US$337.78k	0.00099% € 607.1k

7.0yrs

평균 재임 기간

62yo

평균 연령

경험이 풍부한 이사회: BDX 의 이사회는 경험(평균 재직 기간 7 년)으로 간주됩니다.

Becton Dickinson 관리

관리 기준 확인 3/4

주요 정보

최근 관리 업데이트

BD Names Michael Feld as President of Life Sciences Segment, Effective August 20, 2024

Dave Hickey Retires as Executive Vice President and President of the Life Sciences Segment for BD, Effective from July 1, 2024

Becton, Dickinson and Company, Annual General Meeting, Jan 23, 2024

Becton, Dickinson and Company Announces Executive Changes

BD Names Greg Rodetis as Senior Vice President of Investor Relations

Becton, Dickinson and Company Elects Joanne Waldstreicher to the Board and as Member of the Corporate Governance and Nominating Committee and the Quality and Regulatory Committee of the Board

Recent updates

Third quarter dividend of US$1.04 announced

Becton, Dickinson and Company Has Declares A Quarterly Dividend, Payable on December 31, 2024

Becton, Dickinson and Company Launches Enhanced Intraosseous System, Enabling Vascular Access in Seconds for Critical Care Situations

Becton, Dickinson and Company Announces New Robotics Solution to Automate, Standardize Single-Cell Research

Becton, Dickinson and Company to Report Q4, 2024 Results on Nov 07, 2024

Becton, Dickinson and Company Reaches Multi-Year Settlement in Hernia Mesh Lawsuits

Becton, Dickinson and Company (NYSE:BDX) completed the acquisition of Critical Care Product Group of Edwards Lifesciences Corporation (NYSE : EW).

Upcoming dividend of US$0.95 per share

BD Names Michael Feld as President of Life Sciences Segment, Effective August 20, 2024

Third quarter 2024 earnings released: EPS: US$1.68 (vs US$1.37 in 3Q 2023)

Becton, Dickinson and Company Updates Earnings Guidance for the Year 2024

Second quarter dividend of US$0.95 announced

Becton, Dickinson and Company Declares Quarterly Dividend, Payable on September 30, 2024

Becton, Dickinson and Company to Report Q3, 2024 Results on Aug 01, 2024

BD (Becton, Dickinson and Company) Announces the Commercial Launch of a New Single-Cell Research Tool

Becton, Dickinson and Company (NYSE:BDX) entered into an agreement to acquire Critical Care Product Group of Edwards Lifesciences Corporation (NYSE : EW) for $4.2 billion.

Upcoming dividend of US$0.95 per share

Second quarter dividend of US$0.95 announced

Becton, Dickinson and Company Revises Earnings Guidance for the Fiscal Year 2024

Second quarter 2024 earnings released: EPS: US$1.86 (vs US$1.54 in 2Q 2023)

Becton, Dickinson and Company Declares Quarterly Dividend, Payable on June 28, 2024

Becton, Dickinson and Company (NYSE:BDX) acquired FlowJo LLC.

Becton, Dickinson and Company to Report Q2, 2024 Results on May 02, 2024

Becton, Dickinson and Company Initiates International Study to Expand Treatment Options for Patients with Peripheral Arterial Disease

Upcoming dividend of US$0.95 per share

Dave Hickey Retires as Executive Vice President and President of the Life Sciences Segment for BD, Effective from July 1, 2024

Now 20% overvalued

First quarter 2024 earnings released: EPS: US$0.97 (vs US$1.71 in 1Q 2023)

Becton, Dickinson and Company Raises Earnings Guidance for the Fiscal Year of 2024

Fourth quarter dividend of US$0.95 announced

Becton, Dickinson and Company Declares Quarterly Dividend, Payable on March 29, 2024

Becton, Dickinson and Company to Report Q1, 2024 Results on Feb 01, 2024

Becton, Dickinson and Company, Annual General Meeting, Jan 23, 2024

BD Receives FDA 510(K) Clearance for Potentially Transformative Fingertip Blood Collection Device

Upcoming dividend of US$0.95 per share at 1.6% yield

BD Launches Advanced Vascular Access Ultrasound System Designed to Improve Clinician Efficiency

Becton, Dickinson and Company Announces Executive Changes

Full year 2023 earnings released: EPS: US$5.14 (vs US$5.42 in FY 2022)

Becton, Dickinson and Company Increases Quarterly Dividend, Payable on December 29, 2023

Becton, Dickinson and Company Provides Earnings Guidance for the Fiscal Year 2024

Now 24% undervalued after recent price drop

Becton, Dickinson and Company Announces Launch of Next-Generation Needle-Free Blood Draw Technology

BD Names Greg Rodetis as Senior Vice President of Investor Relations

Becton, Dickinson and Company to Report Q4, 2023 Results on Nov 09, 2023

Upcoming dividend of US$0.91 per share at 1.3% yield

Becton, Dickinson and Company Raises Earnings Guidance for the Fiscal Year 2023

New minor risk - Earnings quality

Third quarter 2023 earnings released: EPS: US$1.37 (vs US$1.29 in 3Q 2022)

Becton, Dickinson and Company Elects Joanne Waldstreicher to the Board and as Member of the Corporate Governance and Nominating Committee and the Quality and Regulatory Committee of the Board

Becton, Dickinson and Company Receives FDA 510(k) Clearance for Updated BD Alaris™? Infusion System

Becton, Dickinson and Company to Report Q3, 2023 Results on Aug 03, 2023

STERIS Corporation agreed to acquire Surgical Instrumentation platform from Becton, Dickinson and Company for $540 million.

Upcoming dividend of US$0.91 per share at 1.5% yield

Second quarter 2023 earnings released

Becton, Dickinson and Company Raises Earnings Guidance for the Fiscal Year 2023

Upcoming dividend of US$0.91 per share at 1.6% yield

BD Receives FDA Emergency Use Authorization for COVID-19, Influenza A/B, RSV Combination Test

Becton, Dickinson and Company Introduces High-Throughput Single-Cell Multiomics Platform to Expand Scope of Scientific Discovery

First quarter 2023 earnings released: EPS: US$1.71 (vs US$2.30 in 1Q 2022)

Becton, Dickinson and Company Provides Earnings Guidance for the Year 2023

BD (Becton, Dickinson and Company) Declares Quarterly Dividend, Payable on March 31, 2023

Becton, Dickinson and Company Introduces Fully Automated Robotic Track System for Microbiology Labs

Becton, Dickinson and Company and CerTest Biotec Announce Emergency Use Authorization from U.S. Food and Drug Administration for Molecular Polymerase Chain Reaction Assay for Mpox Virus Detection

Becton, Dickinson and Company Announces Executive Changes

Becton, Dickinson and Company to Report Q1, 2023 Results on Feb 02, 2023

Becton, Dickinson and Company, Annual General Meeting, Jan 24, 2023

Upcoming dividend of US$0.91 per share

Full year 2022 earnings released: EPS: US$5.42 (vs US$6.92 in FY 2021)

Full year 2022 earnings released: EPS: US$5.42 (vs US$6.92 in FY 2021)